We are delighted to introduce our latest team member, Outi Vilamo and Netta Keinänen was appointed as the new Sales and Marketing Director from the beginning of January 2021
Our scientists presented an awarded poster at the virtual AACC 2020:
“Diverse Short-Term Natriuretic Response in Acute Decompensated Heart Failure Patients Undergoing Entresto™ Treatment"
Juhana Rauramo will become the new CEO of HyTest Group Oy with effect from January 1, 2021. Juhana has proven to be a very valuable person for HyTest and he has agreed to take on a more extensive role regarding the management of the company. Meanwhile, Maria Severina, the Founder and CEO of the company for the last 26 years will continue as a board member for HyTest Group Oy and she will be available as a consultant to the company.
Juhana has been the CCO of HyTest and a member of the management team since September 2019.
In this exceptional year we must make exceptional actions. Check our Season's Greetings video to you:
Connect with our representative during the AACC virtual expo, taking place December 14–17. Schedule a meeting at our booth through the virtual platform or contact us already now and agree a meeting.
Our new Sales Manager Outi Vilamo will be also waiting to meet you there.
We are pleased to let you know that we now have the first four anti-nucleoprotein antibodies available in their final forms.
Clinical Chemistry podcasts are highlighting selected articles in the journal. Now our scientists have been guests in the Clinical Chemistry podcasts related to their publications in the same journal.
Listen below the podcasts and learn more about our cardiac markers.
AACC’s Annual Scientific Meeting & Clinical Lab Expo, taking place December 14–17, will include many activities that you are used to experiencing in a live event: scientific sessions, poster presentations, an Expo showcase and networking opportunities.
If you or a representative of your company is planning to attend, we would welcome the opportunity to meet with you at our virtual booth.
Our first COVID-19 related monoclonal antibodies are now available
Our first COVID-19 related monoclonal antibodies will be soon available: Ten antibodies specific to SARS-CoV-2 nucleoprotein and two antibodies specific to Spike (RBD) will be launched in 2-3 weeks.
In the latest Clinical Chemistry editorial our scientist addresses an article about molecular heterogeneity of NT-proBNP/proBNP published in the same issue. In the editorial our scientist discusses the complexity of this circulating heart failure marker, current NT-proBNP assays and how ongoing research including the addressed article could affect the design of future NT-proBNP assays.
We are pleased to let you know that we are developing several monoclonal antibodies specific to SARS-CoV2 nucleoproteins (Cat.# 3CV4) and to Spike RBD (Cat.# 3CV2).
By watching this webinar, you will learn about:
- transmission and clinical characteristics of SARS-CoV-2
- the existing testing methods for SARS-CoV-2, including nucleic acid testing, genome sequencing, serological testing for SARS-CoV-2 specific antibodies and antigen testing
- the principles, advantages and limitations of these testing methods
- safety precautions for handling different types of clinical specimens for SARS-CoV-2 detection
HyTest’s SARS-CoV-2 Nucleoprotein (Cat.# 8COV3) is a full-length recombinant antigen that can be used in serology assays for the detection of COVID-19 specific antibodies.
Soluble ST2 (sST2) biomarker is used for additive risk stratification and prognosis of patients with heart failure (HF). ST2 interacts with IL-33, and IL-33/ST2 system is upregulated in cardiomyocytes and fibroblasts in response to cardiac injury or cardiac stress.
HyTest’s recombinant SARS-CoV-2 Spike RBD is now available. The antigen can be used in the development of COVID-19 serology (antibody) tests.
We are finalizing the development of SARS-CoV-2 Nucleoprotein. The antigen can be used in serology assays.
We have now developed a recombinant GFAP protein that can be used as a standard or calibrator in GFAP immunoassay development
Insulin-like growth factor binding protein-4 (IGFBP-4) fragments have been shown to predict the risk of major adverse cardiovascular events, including segment-elevation myocardial infarction, in patients with acute coronary syndrome.